One potential solution to the Trump administration's more assertive posture on pharmaceutical pricing in benchmark countries like Australia is to raise the published list PBS price paid to manufacturers. Yet it could have unintended consequences.
A simple increase in published list prices could have unintended consequences
February 10, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
Scientists identify highly specific targets that could transform multiple myeloma treatment
March 15, 2026 - - Australian Biotech -
Australians turn to local pharmacies as frontline of everyday healthcare
March 13, 2026 - - Latest News -
Sandoz and Camp Quality unite to strengthen support for Australian families facing childhood cancer
March 13, 2026 - - Latest News -
The leadership challenge behind Australia’s medicine access gap
March 13, 2026 - - Latest News -
Australia’s top community pharmacists honoured at national awards
March 13, 2026 - - Latest News -
Australia has spent four decades having the wrong conversation about medicines access
March 13, 2026 - - Latest News -
‘An absolute medical miracle’ - MPs highlight progress and challenges at Cystic Fibrosis event
March 13, 2026 - - Latest News

